BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...the A round, and Foresite Capital, Bluebird Ventures, Narya Capital, existing investor Amplo, Paul Manning, Asia Alpha...
...$80.5 million Investors: QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Paul Manning, Asia Alpha...
Items per page:
1 - 1 of 1
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...the A round, and Foresite Capital, Bluebird Ventures, Narya Capital, existing investor Amplo, Paul Manning, Asia Alpha...
...$80.5 million Investors: QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Paul Manning, Asia Alpha...
Items per page:
1 - 1 of 1